Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case report describes a patient with severe alopecia totalis and atopic dermatitis who showed almost complete hair regrowth and improved skin lesions after receiving subcutaneous allergen-specific immunotherapy using house dust mites.

This article discusses the potential of novel microneedle transdermal systems for enhanced drug and vaccine delivery through the skin, but reports no clinical results and emphasizes ongoing trials.

This study reported that the prevalence of atopic dermatitis in cats was higher than previously suggested, with severe nonseasonal pruritus most common, and certain breeds were predisposed.

The document concludes that various hypersensitivity diseases in horses can be diagnosed and treated with methods like immunotherapy and medication, and early aggressive treatment is crucial for severe diseases like equine cutaneous pythiosis.

This report describes common cutaneous reaction patterns in cats with non-flea induced hypersensitivity dermatitis but does not provide new experimental findings or results.

This review discusses allergic reactions to pollen in dogs, cats, and horses and suggests that these animals' spontaneous allergies could serve as models for translational clinical studies applicable to human allergies.

This study found that adding allergen immunotherapy to conventional treatment may reduce relapse-related hair loss in house dust mite-allergic alopecia areata patients over a 3-year period.

This review examines the potential of mesenchymal stem/stromal cells in treating and possibly preventing allergic diseases, and reports no new clinical results.

Cats with Feline Symmetrical Alopecia can regrow hair with proper treatment based on the specific cause, including diet, medication, or stress management.

This letter discusses immunotherapy for severe or resistant alopecia areata in a university hospital in Northern Mexico and reports no new results.

This study examines the use of diphenylcyclopropenone in treating alopecia areata patients at the University Hospital Würzburg and investigates how the treatment affects patients' quality of life.

This review summarizes the pathophysiology and immune mechanisms of inflammatory skin diseases like psoriasis and atopic dermatitis, highlighting the therapeutic potential of targeted immunotherapies, but reports no new clinical results.

The 2006 editorial concluded that immunotherapy was advancing with new drugs, focusing on specific biological therapies and convenient oral treatments, and highlighted the importance of partnerships and new regulations in the field.

This article discusses the etiology, clinical features, diagnosis, histopathology, and treatment of alopecia areata but reports no new clinical findings; it emphasizes the palliative nature of current treatments.

This review discusses the evolution of alopecia areata treatments towards more targeted therapies and reports no new clinical results, emphasizing cooperation between clinicians and scientists in understanding the disease's pathophysiology.

In this study, researchers observed that patients with alopecia areata who followed an elimination diet targeting specific food and pollen allergens showed clinical improvement, supporting a role for food allergy in the condition.

This study observed significant differences in immune cell infiltration and gene expression across different skin sites, with the back displaying higher tolerance-promoting immune mechanisms, which may enhance epicutaneous immunotherapy outcomes.

This article reviews topics from the American Academy of Veterinary Dermatology and American College of Veterinary Dermatology Annual Meeting and contains no new clinical findings.

This study found that alopecia areata patients who responded poorly to topical immunotherapy had impaired peripheral blood mononuclear cell responses to T-cell stimulants.

This review summarizes current evidence on the use of contact immunotherapy, excluding alopecia areata, for various skin diseases, discussing its safety, efficacy, and the underlying mechanisms as reported from studies in the PubMed database.

This study found that diphencyprone showed a significant clinical response for treating alopecia areata, while tacrolimus was not effective.

This study found that a significant portion of alopecia areata patients achieved at least partial hair regrowth with diphenylcyclopropenon therapy, which was more effective in certain subtypes and disease durations.

In this study, researchers identified a specific T cell receptor associated with carbamazepine-induced severe cutaneous adverse reactions, demonstrating its potential for therapeutic development in patients with the HLA-B*15:02 genotype.

This review outlines various dermatologic adverse events associated with targeted therapies and immunotherapies, emphasizing the need for collaboration between dermatologists and oncologists to manage these effects effectively; it reports no new clinical findings.

In this case report, two plywood mill workers developed allergic contact dermatitis due to exposure to uncured phenol-formaldehyde resin, not sawdust as initially suspected.

This review addresses alopecia areata, emphasizing its autoimmune nature, unpredictable course, and lack of preventive or curative treatments, while noting standard and emerging therapies such as topical steroids and Janus kinase inhibitors.

This review discusses neutrophil-associated and infiltrative scarring alopecias, as well as promising new treatments, but reports no new clinical results.

These guidelines for alopecia areata management, prepared by the British Association of Dermatologists, provide evidence-based treatment recommendations and insights into the condition's epidemiology, diagnosis, and investigation.

This review discusses the advancements in understanding and treating androgenetic alopecia and alopecia areata but reports no clinical findings; the authors emphasize the need for further research on molecular control mechanisms.

This article reviews recent updates on alopecia areata, focusing on its causes, clinical presentation, and treatment options, and provides treatment plans by patient age and disease extent, but reports no new clinical results.